Categories: News

Australian Dentists Endorse Smartee’s Mandibular Repositioning Technology at Global Symposium in Kunming

Clinicians praise the S8-SGTB appliance for accelerating outcomes, improving patient satisfaction, and offering a non-invasive solution for Class II malocclusions.

- Advertisement -

KUNMING, China, July 11, 2025 /PRNewswire/ — Smartee Denti-Technology recently welcomed orthodontic experts and partners from Australia at its Global Symposium in Kunming, China. The event offered a deep dive into Smartee’s Mandibular Repositioning Technology and showcased its clinical applications, particularly the innovative S8-SGTB appliance for Class II skeletal malocclusions. Australian clinicians praised the device for its simultaneous orthopedic and orthodontic correction, shorter treatment duration, and patient-friendly design.

- Advertisement -

Dr. Knox Kim, Principal Dentist at Dental Clinic @ World Tower Sydney, shared:

- Advertisement -

“In the past, for treating Class II malocclusions in growing patients, we had to use twin-block appliances before starting aligner therapy. It took at least three to six months to see the improvement. But with Smartee, from my own experience, it only took about one or two weeks before the patient could notice the lower jaw was pushing forward. And when I show the patients and the patients’ parents the before and after photos, they were very happy to see such a quick response and improvement.”

- Advertisement -

Dr. Jenny J. Song from Blossom Dental Care added:

- Advertisement -

“Compared to traditional functional and fixed appliances, Smartee GS is intelligently designed to guide both mandible repositioning and teeth movement simultaneously. This not only reduces total treatment time but also improves the predictability of outcomes.”

- Advertisement -

Dr. Sabrina Liu, a general dentist in Sydney, reflected:

- Advertisement -

“This seminar was eye-opening. The number of successful mandibular repositioning cases using Smartee GS aligners changed my perception of what clear aligners can achieve. I hope more dentists in Australia will learn about this technique to benefit their patients.”

- Advertisement -

At the core of Smartee’s Mandibular Repositioning Technology is  S8-SGTB, a clear, non-invasive appliance designed to treat skeletal Class II discrepancies, minimizing the need for jaw surgeries or extractions. Engineered for both growing and adult patients, it integrates orthopedic and orthodontic functions in a single aligner-based solution.

- Advertisement -

Key features include:

- Advertisement -
  • Simultaneous mandibular repositioning and dental alignment
  • Anotomical occlusal splints and locking components for stable joint advancement
  • Minimizing need for extractions or surgeries
  • Discreet, comfortable design compared to bulky functional devices

The S8-SGTB represents Smartee’s commitment to delivering clinically effective, patient-centered treatment paths for complex cases.

- Advertisement -

Learn more about Smartee Mandibular Repositioning, please visit https://www.smarteealigners.com/products/smartee-gs-mandibular-repositioning-aligners/

- Advertisement -

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/australian-dentists-endorse-smartees-mandibular-repositioning-technology-at-global-symposium-in-kunming-302503209.html

- Advertisement -

Recent Posts

Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine…

6 minutes ago

Manipal Hospitals Enhances Movement and Confidence Through Awareness on Movement Disorders

BENGALURU, India, Dec. 8, 2025 /PRNewswire/ -- Parkinson's disease often begins far more quietly than…

6 minutes ago

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction…

6 minutes ago

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

TOKYO, Dec. 8, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment…

6 minutes ago

ADFW Opens with Spotlight on Abu Dhabi’s Global Ambition and Major Humanitarian Pledge

ABU DHABI, UAE, Dec. 8, 2025 /PRNewswire/ -- Abu Dhabi Finance Week (ADFW) 2025 opened…

1 hour ago